Biofarm recorded a turnover of 208.9 million RON, up 17 percent, and a net profit of 65.7 million lei, up 20 percent, for the first nine months of 2022. At the same time, Biofarm recorded EBITDA of 89.4 million RON, up 18 percent compared to the first nine months of the previous year.

“The very good results recorded in the last nine months validate our strategy of offering customers innovative products that contribute to their well-being. At the beginning of this year, we set out to introduce new products to the market that become category leaders and we have achieved this with Biofen Extra, which dominates the pain management category in the ibuprofen and paracetamol segment. Biofarm will continue to develop its portofolio through line extensions or new product launches and we aim to expand into new markets,” said Catalin Vicol, Biofarm CEO.

The therapeutic area that has seen the highest growth in the Consumer Healthcare (CHC) category over the last period has been Colds & Flu. Biofarm brands covering this therapeutic area, such as Carmol, Bixtonim Xylo, Septsosol, Bioflu have seen double-digit growth.